Business Context and Reporting Period
The filing is a Form 10-K for NeuroBo Pharmaceuticals, Inc., not Metavia Inc., covering the fiscal year ended December 31, 2023. NeuroBo is a clinical-stage biotechnology company developing cardiometabolic therapies, principally DA-1241 for MASH and type 2 diabetes and DA-1726 for obesity. The company has no approved products or product revenue.
- DA-1241 was in a U.S. Phase 2a MASH trial initiated in August 2023; top-line results were expected by the end of 2024.
- DA-1726 received FDA Phase 1 IND approval; initiation of a Phase 1 trial was planned for the first half of 2024.
- Four legacy programs were not expected to enter further clinical trials and were being considered for out-licensing or divestiture.
Financial Metrics
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No product revenue |
| Research and development expense | $9.2 million | $2.8 million | Up 229.7% |
| Acquired in-process R&D | $0 | $8.2 million | Down $8.2 million |
| General and administrative expense | $6.7 million | $8.6 million | Down 22.1% |
| Total operating expenses | $15.9 million | $19.6 million | Down 19.1% |
| Loss from operations | $(15.9) million | $(19.6) million | Improved |
| Net loss | $(12.5) million | $(14.0) million | Improved |
| Basic and diluted loss per share | $(2.46) | $(43.42) | Improved, affected by share count changes |
| Net cash used in operating activities | $(10.8) million | $(11.7) million | Improved 7.8% |
| Cash and cash equivalents | $22.4 million | $33.4 million | Down $10.9 million |
| Accumulated deficit | $108.3 million | $95.8 million | Increased $12.5 million |
Other income was $3.4 million, including a $3.0 million gain from the change in fair value of warrant liabilities and $0.5 million of interest income. The company reported no income tax expense because its deferred tax assets were fully offset by a valuation allowance.
At December 31, 2023, total liabilities were $6.1 million, including $0.7 million of warrant liabilities, $4.4 million of accrued liabilities and $0.2 million of lease liabilities. The filing does not disclose conventional funded debt.
Material Changes Versus the Prior Comparable Period
- R&D spending increased substantially as development of DA-1241 and DA-1726 progressed. The company incurred $2.4 million under its related-party Shared Services Agreement with Dong-A, including manufacturing and preclinical services.
- The $8.2 million 2022 acquired in-process R&D charge related to the Dong-A license did not recur in 2023.
- Warrant-related noncash income declined to $3.0 million from $7.9 million, while outstanding warrants declined through cashless conversions and exercises.
- Common shares outstanding increased to 4.9 million at December 31, 2023 from approximately 3.2 million at December 31, 2022, principally reflecting warrant exercises and conversions.
- The company completed a one-for-eight reverse stock split in December 2023. Historical share and per-share amounts were adjusted accordingly.
- Cash declined by $10.9 million during 2023, with operating cash use only partly offset by minimal investing and financing activity.
Liquidity, Outlook, Risks and Unusual Items
Management stated that the $22.4 million cash balance was expected to fund operations into the fourth quarter of 2024. The financial statements state that recurring losses and negative operating cash flows raise substantial doubt about the company’s ability to continue as a going concern. Additional financing is expected to be required through equity, debt, collaborations, licensing or other arrangements. Potential equity financing could materially dilute existing stockholders.
- Dong-A owns approximately 57% of the company’s outstanding common stock and has significant control over corporate actions and board nominations.
- The Dong-A license requires potential regulatory milestone payments of up to $178.0 million for DA-1726 and $138.0 million for DA-1241, commercial milestones and single-digit royalties on future net sales. No milestone liabilities were recorded because the milestones were not considered probable.
- Dong-A is the sole manufacturer of DA-1241 and DA-1726 under the Shared Services Agreement, creating supplier and manufacturing concentration risk.
- The company identified material weaknesses in internal control over financial reporting involving segregation of duties, logical access controls, and management review of financial reporting. Remediation was ongoing during 2024.
- Clinical development, regulatory approval, patient enrollment, adverse events, competition, intellectual property protection and access to capital remain significant uncertainties.
- The company reported no material pending legal proceedings and no material off-balance-sheet arrangements.
- The Pfizer license for Gemcabene included a provision permitting termination if a commercial sale was not made by April 2024; management was considering the legacy program for out-licensing or divestiture.
Most Important Facts to Verify
- Confirm that the supplied filing belongs to NeuroBo Pharmaceuticals, Inc. rather than Metavia Inc.
- Verify the company’s cash runway, financing plans and ability to fund operations beyond the fourth quarter of 2024.
- Track enrollment, safety findings and top-line results for the DA-1241 Phase 2a trial.
- Confirm initiation and progress of the DA-1726 Phase 1 trial.
- Assess the probability, timing and funding implications of Dong-A regulatory and commercial milestone payments.
- Evaluate remediation of the disclosed material weaknesses in internal control over financial reporting.
- Monitor dilution from equity financing, outstanding warrants, restricted stock units and the controlling ownership position of Dong-A.
- Review the full audited financial statements and notes for accrued clinical trial costs, related-party balances and warrant liability valuation.